Literature DB >> 14608099

Glucagon-like peptide-2 and intestinal adaptation: an historical and clinical perspective.

R Hermon Dowling1.   

Abstract

Of the many models of intestinal adaptation, the structural and functional changes seen in the residual small bowel following jejunectomy or ileectomy are the most predictable and best studied. There are three major mechanisms for these adaptive phenomena: changes in i) luminal nutrition, ii) pancreatico-biliary secretions and iii) hormonal factors. Observations in a unique patient with an "enteroglucagon"-secreting tumor of the kidney associated with massive small bowel enlargement, provided the strongest evidence, at that time (>30 y ago), in favor of hormonal factors. When the patient's renal tumor was removed, the markedly increased circulating concentrations of the glucagon-like peptide (now presumed to be GLP-2) returned to normal-as did her intestinal anatomy. Subsequent studies showed that there are increased tissue and plasma enteroglucagon (and recently GLP-2) levels in many animal models of intestinal adaptation. This, and anecdotal evidence from three other case reports, coupled with contemporary studies of GLP-2, strongly suggest that this glucagon-like peptide is a potent, but not the sole, enterotrophin.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14608099     DOI: 10.1093/jn/133.11.3703

Source DB:  PubMed          Journal:  J Nutr        ISSN: 0022-3166            Impact factor:   4.798


  2 in total

1.  Control of Intestinal Epithelial Proliferation and Differentiation: The Microbiome, Enteroendocrine L Cells, Telocytes, Enteric Nerves, and GLP, Too.

Authors:  Jonathan D Kaunitz; Yasutada Akiba
Journal:  Dig Dis Sci       Date:  2019-10       Impact factor: 3.199

2.  Metabolic effects of an entero-omentectomy in mildly obese type 2 diabetes mellitus patients after three years.

Authors:  Fábio Quirilo Milleo; Antonio Carlos Ligocki Campos; Sérgio Santoro; Arnaldo Lacombe; Marco Aurélio Santo; Marcelo Ricardo Vicari; Viviane Nogaroto; Roberto Ferreira Artoni
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.